Inovio Pharmaceuticals (INO) Unlikely to be a COVID Vaccine Contender, Roth Capital Reiterates Sell
Tweet Send to a Friend
Roth Capital analyst Jonathan Aschoff reiterated a Sell rating and $11.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE